Hosted on MSN1mon
Merck gets priority review for Welireg for PPGL
Merck (NYSE:MRK) is seeking to have the drug approved for the treatment of patients 12 years and older with advanced, unresectable or metastatic pheochromocytoma and paraganglioma, or PPGL.
Nature3y
First FDA-approved treatment for an ultra-rare disease
“PPGL includes all of these tumours; they can arise anywhere from the base of the skull down to the bladder.” As PPGLs are rare, obtaining evidence to prove the safety and efficacy of a ...
Pharm Exec1mon
FDA Grants Priority Review to Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma
Currently, there are no approved therapies for PPGL in the United States. 1 “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently, there are no ...
Yahoo Finance1mon
MSD wins FDA priority review for Welireg in rare endocrine cancer
The new label is intended to cover adult and paediatric patients aged 12 years and older with advanced, unresectable, or metastatic PPGL. MSD’s submission is based on efficacy and safety data ...
Morningstar25d
PT Prima Globalindo Logistik Tbk Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Nature3y
The first FDA approved treatment for ultra-rare endocrine tumors
Fortunately, there is now an effective treatment available for patients with unresectable, locally advanced or metastatic pheochromocytoma and paraganglioma (PPGL). A recent review in Cancers from ...